EIKNEikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc. Common Stock (EIKN) is a biotechnology firm focused on oncology drug development, with a pipeline centered on antibody-drug conjugates (ADCs) and other novel cancer therapies. The next catalyst is October 22, 2026 — FDA Fast Track Designation Decision, which will test whether the agency will grant expedited review for its lead asset, EIK1001, based on its Phase 2 trial data.
- The company has a negative net income of $359.54M and a diluted EPS of -1.63 as of 2026-06-30.
- Free cash flow (TTM) is -$453.55M, reflecting heavy R&D investment.
- Shareholders’ equity stands at $466.50M, indicating a leveraged capital structure.
The Read
3% after Phase 1 safety data failed to meet expectations, then declined further amid a missed secondary offering, but rallied 6% on Q2 earnings and clinical updates that reassured investors about its pipeline and cash runway.
The schedule
- Thu22Oct
The FDA's decision on the Fast Track designation will test the company's ability to secure regulatory support for its pipeline, which could influence investor confidence and valuation.
- Fri30Oct
The earnings release will test whether the company can deliver a positive guidance reset, particularly on cash runway and mix, following the recent secondary offering that pressured the stock.
- Tue8Dec
The R&D Strategy Day will test the company's ability to outline its long-term research and development plans, which could influence investor confidence and valuation.
- Sun17Jan
This earnings release will test the company's ability to maintain its guidance and show progress in clinical trials, which could influence investor sentiment and valuation.
- Sun18Apr
The Q1 2027 earnings release will test the company's ability to show progress in clinical trials and maintain its guidance, which is critical for investor confidence and valuation.
- Wed11Aug
The Q2 2027 earnings release will test the company's ability to show progress in clinical trials and maintain its guidance, which is critical for investor confidence and valuation.
Past
- Wed12Aug
Actual outcome: Bull · $11.05 at outcome
Eikon Therapeutics reported Q2 2026 earnings with EPS exactly in line with estimates (-$1.53) and provided clinical updates on its late-stage pipeline. The absence of negative surprises regarding its aggressive R&D spend and the reassurance from its clinical progress drove investor confidence, pushing the stock up 6% to exceed the $10.00 bull target.
The Q2 earnings report will provide a critical update on the balance sheet, capital maneuvers, and the trajectory of the company's aggressive R&D spend.
- Tue14Jul
Actual outcome: Bear · $9.95 at outcome
The anticipated secondary equity offering did not materialize during the target window, resulting in a muted 2.4% decline by the outcome date. Without a definitive capital raise to drive a sharp directional move, price action remained ambiguous before the company later announced seven abstract presentations for the upcoming ESMO Congress, which helped lift the stock in the following weeks.
With an operating cash flow of -$89.8M and a substantial debt load of $254M, EIKN's rapid cash burn makes a secondary equity offering highly probable in the near term to secure runway.
- Mon18May
Actual outcome: Bear · $10.66 at outcome
Eikon Therapeutics released abstracts for the upcoming ASCO annual meeting, providing updated clinical data on its lead oncology programs, including EIK1001. The stock fell 9.3% around the readout and continued to decline toward the bear floor, indicating that the initial safety and tolerability data failed to meet investor expectations.
Initial safety and tolerability data for the lead oncology candidate developed via the super-resolution microscopy platform.
